1. Medtech Insight
  2. >>Business

MTI 100 Review: Medtechs Drive To Keep The Status Quo In A Year Like No Other

Medtech Insight's review of the industry's leading companies' revenue performances in 2020 kicks off our 2022 Outlook Analysis

 
• By Ashley Yeo

The performances of the leading medtechs in the first year of the COVID pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management's planning skills.

financial chart

Demand and supply of certain types of medtech, industrial operations, supply chains and distribution systems were all impacted, to a greater or lesser extent, by COVID-19 in 2020. So were product development milestones, clinical trials, regulatory clearances and approval timings.

All companies were affected one way or another. Most leading orthopedic and some cardiology suppliers often saw sharply negative outcomes, while the opposite was the case for companies whose devices...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

Execs On The Move: 5-9 May 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.